HealthMarketsupdated today

Does the FDA approve Cogent's bezuclastinib for GIST?

Will the FDA approve Cogent Biosciences' bezuclastinib, in combination with sunitinib, for second-line gastrointestinal stromal tumors (GIST) by its November 30, 2026 PDUFA target action date, rather than issuing a Complete Response Letter or missing that date?

80% yes — FDA approves bezuclastinib for GIST

No formal approval-probability model is public; a positive Phase 3 readout and Priority Review designation point toward a high base rate for approval

Bulls note PEAK met its primary endpoint with a large, clinically meaningful PFS benefit and the FDA's own Priority Review grant signals confidence in the data package — a combination that historically clears approval at a high rate. Skeptics note bezuclastinib still carries class-wide KIT-inhibitor safety considerations the agency could flag late in review, and that Cogent has no prior approved product, leaving execution and manufacturing-inspection risk that larger, previously-approved sponsors don't carry into a first NDA decision.

Resolves Nov 30, 2026 · FDA PDUFA target action date for the bezuclastinib (plus sunitinib) GIST NDA

Cogent's Phase 3 PEAK trial (announced topline in Nov 2025) showed bezuclastinib plus sunitinib extended median progression-free survival to 16.5 months versus 9.2 months for sunitinib alone in imatinib-resistant second-line GIST, with full data presented at ASCO 2026 showing average treatment duration around 21.4 months. The FDA accepted the NDA with Priority Review and set a November 30, 2026 target action date — a faster, six-month review clock than the standard-review anito-cel filing elsewhere on this site, reflecting the strength of the PEAK data package. Approval would give Cogent its first commercial product and put it in direct competition with two already-approved, commercially established GIST therapies: Blueprint Medicines' Ayvakit (avapritinib) and Deciphera's Qinlock (ripretinib).

The FDA either approves the NDA by its stated target action date or it doesn't (a Complete Response Letter, a delay, or an extended review all count as no) — a discrete regulatory decision due on a published date.

Researched Nov 2, 2026 · tracked since Nov 2, 2026

What do you think?

Take a side

FDA approves bezuclastinib for GISTthis is “yes”

The Phase 3 PEAK trial met its primary endpoint with a large, clinically meaningful PFS benefit (16.5 vs 9.2 months), the FDA granted Priority Review rather than standard review, and no clinical hold or safety signal has been reported.

Long

COGT Cogent Biosciences, Inc.The NDA sponsor; approval would be Cogent's first-ever commercial product launch and validate its KIT-inhibitor franchise, while a CRL would be a major setback to its lead asset.

Long

XBI SPDR S&P Biotech ETFBroad biotech-sentiment barometer; a high-profile Priority Review approval in a closely-watched solid-tumor indication is a modest positive-sentiment catalyst for the sector generally.

Long

IBB iShares Biotechnology ETFA second, more large-cap-weighted biotech sector proxy; moves with the same diluted sentiment logic as XBI.

Short

BPMC Blueprint Medicines CorporationMarkets Ayvakit (avapritinib), an already-approved GIST therapy; a denied or delayed bezuclastinib approval removes a direct new competitor from the second-line GIST market Blueprint depends on.

Short

DCPH Deciphera Pharmaceuticals, Inc.Markets Qinlock (ripretinib), the other already-approved later-line GIST therapy; benefits similarly to Blueprint from one fewer approved competitor in the same indication.

Short

SPLV Invesco S&P 500 Low Volatility ETFA low-volatility factor proxy; a CRL or delay for a widely-watched speculative biotech catalyst is a relative tailwind as capital rotates away from high-beta small-cap biotech risk.

Worth knowing: Cogent has no prior approved product, so this filing also tests the company's first manufacturing and labeling review with the FDA — a risk larger, previously-approved sponsors don't carry into a first NDA decision.

FDA delays or rejects bezuclastinib

A first-time NDA sponsor faces manufacturing and inspection scrutiny that experienced filers don't, KIT-inhibitor class safety considerations could draw a late-review query, and this year has already shown several sponsors miss PDUFA dates or receive CRLs despite accepted, even priority-reviewed, filings.

Short

IBB iShares Biotechnology ETFA second, more large-cap-weighted biotech sector proxy; moves with the same diluted sentiment logic as XBI.

Long

Worth knowing: Priority Review itself is a meaningful positive signal the FDA saw urgency and strength in the data package — don't read generic first-time-filer caution as a strong signal against this specific, already-accepted filing.

4 sources, leaning both ways

mixedBioSpace — Cogent Biosciences Announces FDA Acceptance of New Drug Application for BezuclastinibChecked Nov 2: confirms Cogent's broader PDUFA calendar across indications; GIST decision separately dated Nov 30, 2026 per company and tracker disclosures.
yesBarchart (press release wire) — Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in GISTChecked Nov 2: primary trial-sponsor results — PEAK met its primary PFS endpoint (16.5 vs 9.2 months).
yesApplied Clinical Trials — Bezuclastinib + Sunitinib Achieves Strong PFS Benefit in PEAK Trial for Imatinib-Resistant GISTChecked Nov 2: independent trade-press coverage of the PEAK PFS data underlying the NDA.
mixedSeeking Alpha — Cogent Biosciences (COGT) Discusses Positive Phase 3 PEAK Trial Results of BezuclastinibChecked Nov 2: management call discussion of the data and regulatory path, including competitive positioning against Ayvakit and Qinlock.